BioXcel Therapeutics, Inc. (BTAI)
Summary
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1.5 per share a year ago.
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 1.91M | $2.56M | $1.76M | -$802,232.11 | -31.34% |
 Olalekan F. Adeduji Washington Trust Advisors Inc. | 160 | $324.8 | $140.19 | -$184.61 | -56.84% |
 Christopher C. Powers Farther Finance Advisors, LLC | 25 | $40 | $22.06 | -$17.94 | -44.85% |
 Jay Annis Annis Gardner Whiting Capital Advisors, LLC | 156 | $239.23 | $137.69 | -$101.54 | -42.44% |
| DWM Diversify Wealth Management LLC DIVERSIFY WEALTH MANAGEMENT, LLC | 15,000 | $27,150 | $13,239 | -$13,911 | -51.24% |
BioXcel Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GM Geoff Meacham B of A Securities | - | - | - | - | - |
BioXcel Therapeutics, Inc. (BTAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioXcel Therapeutics, Inc. ever had a stock split?
BioXcel Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Vimal D. Mehta CEO | NASDAQ (CM) Exchange | 09075P204 CUSIP |
| US Country | 29 Employees | - Last Dividend | 10 Feb 2025 Last Split | 8 Mar 2018 IPO Date |
Overview
BioXcel Therapeutics, Inc. is at the forefront of the biopharmaceutical industry, distinguished by its innovative application of artificial intelligence (AI) to discover and develop groundbreaking medicines in the fields of neuroscience and immuno-oncology. Founded in 2017 and based in New Haven, Connecticut, this commercial-stage company is pioneering a unique drug re-innovation strategy. This approach integrates the use of approved drugs or clinically validated product candidates with the analysis of big data and proprietary machine learning algorithms, aiming to unearth new therapeutic applications. By blending technology with science, BioXcel Therapeutics endeavors to expedite the delivery of transformative treatments to patients, addressing acute and chronic conditions with unmet medical needs.
Products and Services
- IGALMI
- BXCL501
- BXCL502
- BXCL701
- BXCL503 and BXCL504
A breakthrough in the treatment of agitation, IGALMI is a sublingual film formulation of dexmedetomidine. This commercial product is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. By providing a non-invasive, rapidly acting solution, IGALMI represents a significant advancement in managing these complex conditions.
BioXcel Therapeutics is actively conducting clinical trials to expand the use of BXCL501, a proprietary, orally dissolving film of dexmedetomidine. The ongoing studies aim to evaluate its effectiveness for the acute treatment of agitation in Alzheimer's disease, as an adjunctive treatment in major depressive disorder, and for use in community settings for managing agitation related to bipolar disorders and schizophrenia. This versatile candidate underscores the company's commitment to addressing a broad spectrum of neuropsychiatric disruptions.
In development as a potential therapy for chronic agitation in dementia, BXCL502 represents BioXcel Therapeutics' aim to enhance the quality of life for individuals suffering from this longstanding condition. This initiative is a testament to the company's ongoing efforts to address difficult-to-treat aspects of dementia through innovative therapeutic interventions.
BXCL701 is an investigational orally administered innate immunity activator under evaluation for treating aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. Its development demonstrates BioXcel Therapeutics' dedication to extending its AI-driven approach to the realm of immuno-oncology, offering hope for patients with limited treatment options.
These investigational drug candidates, BXCL503 and BXCL504, are aimed at targeting behavioral symptoms associated with dementia, such as apathy and aggression. By focusing on these specific aspects of dementia care, BioXcel Therapeutics is addressing critical gaps in the current treatment landscape, potentially improving the daily life of those affected by these conditions.
